---
title: "ELDN.US (ELDN.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ELDN.US/news.md"
symbol: "ELDN.US"
name: "ELDN.US"
parent: "https://longbridge.com/en/quote/ELDN.US.md"
datetime: "2026-05-22T00:05:58.413Z"
locales:
  - [en](https://longbridge.com/en/quote/ELDN.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ELDN.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ELDN.US/news.md)
---

# ELDN.US (ELDN.US) — Related News

### [Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress](https://longbridge.com/en/news/287114656.md)
*2026-05-20T20:07:54.000Z*
> Eledon will be showcasing updated long-term results from the Phase 2 BESTOW trial of Tegoprubart at the upcoming ATC con

### [Eledon Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/286350711.md)
*2026-05-14T03:21:31.000Z*
### [Eledon Pharmaceuticals (ELDN) Expected to Announce Earnings on Wednesday](https://longbridge.com/en/news/285356473.md)
*2026-05-06T10:30:27.000Z*
> Eledon Pharmaceuticals (NASDAQ:ELDN) is set to announce its Q1 2026 earnings on May 13, with analysts predicting a loss 

### [NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference | NCEL Stock News](https://longbridge.com/en/news/283345845.md)
*2026-04-20T03:37:00.000Z*
> NewcelX Ltd. (Nasdaq: NCEL) has updated its corporate presentation to emphasize its strategic collaboration with Eledon 

### [Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines | ELDN Stock News](https://longbridge.com/en/news/281782349.md)
*2026-04-06T09:15:37.000Z*
> Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines | ELDN Stock News

### [Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3%](https://longbridge.com/en/news/280917464.md)
*2026-03-29T17:52:32.000Z*
> Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) experienced a 30.3% increase in short interest in March, totaling 8,417,915 s